NANO Nanobiotix SA

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA
EN
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE

NANOBIOTIX to Participate in Investor Conferences the Week of November...

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: UBS Global Healthcare ConferenceDate: Monday, November 10, 2025Time: 5pm ET / 11pm CETLocation: Palm Beach Gardens, FLPresenter: Bart va...

 PRESS RELEASE

NANOBIOTIX participera à des conférences investisseurs la semaine du 1...

NANOBIOTIX participera à des conférences investisseurs la semaine du 10 novembre PARIS et CAMBRIDGE, Mass., 03 nov. 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui qu’elle participera à des discussions (« fireside chat ») aux conférences suivantes : UBS Global Healthcare ConferenceDate : lundi 10 novembre 2025...

Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch